TY - JOUR
T1 - Group for research and assessment of psoriasis and psoriatic arthritis
T2 - treatment recommendations for psoriatic arthritis 2015
AU - Coates, Laura C
AU - Kavanaugh, Arthur
AU - Mease, Philip J
AU - Soriano, Enrique R
AU - Laura Acosta Felquer, Maria
AU - Armstrong, April W
AU - Bautista Molano, Wilson
AU - Boehncke, Wolf-Henning
AU - Campbell, Willemina
AU - Cauli, Alberto
AU - Espinoza, Luis R
AU - FitzGerald, Oliver
AU - Gladman, Dafna D
AU - Gottlieb, Alice
AU - Helliwell, Philip S
AU - Elaine Husni, M
AU - Love, Thorvardur J
AU - Lubrano, Ennio
AU - McHugh, Neil
AU - Nash, Peter
AU - Ogdie, Alexis
AU - Orbai, Ana-Maria
AU - Parkinson, Andrew
AU - O'Sullivan, Denis
AU - Rosen, Cheryl F
AU - Schwartzman, Sergio
AU - Siegel, Evan L
AU - Toloza, Sergio
AU - Tuong, William
AU - Ritchlin, Christopher T
PY - 2016/5
Y1 - 2016/5
N2 - OBJECTIVE: Update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting patients with psoriatic arthritis (PsA).METHODS: GRAPPA rheumatologists, dermatologists, and PsA patients drafted overarching principles for the management of PsA patients based on consensus at face-to-face meetings and via online surveys. We published literature reviews regarding treatment for the key domains of PsA (arthritis, spondylitis, enthesitis, dactylitis, skin, and nail disease), and convened a new group to identify pertinent comorbidities and their effect on treatment. Finally, we drafted treatment recommendations for each of the clinical manifestations and assessed the level of agreement for the overarching principles and treatment recommendations among GRAPPA members, with an online questionnaire.RESULTS: Six overarching principles had at least 80% agreement among both health care professionals (HCPs; n=135) and patient research partners (PRPs; n=10). We developed treatment recommendations and a schema incorporating these principles for arthritis, spondylitis, enthesitis, dactylitis, skin, and nail disease, and comorbidities in the setting of PsA, using the GRADE process. Over 80% agreement was reached for approval of the individual recommendations and the overall schema.CONCLUSION: Herein, we present overarching principles and updated treatment recommendations for the key manifestations of PsA, including related comorbidities, based on a literature review and consensus of GRAPPA members (rheumatologists, dermatologists, other HCPs, and PRPs). Further updates are anticipated as the therapeutic landscape in PsA evolves.
AB - OBJECTIVE: Update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting patients with psoriatic arthritis (PsA).METHODS: GRAPPA rheumatologists, dermatologists, and PsA patients drafted overarching principles for the management of PsA patients based on consensus at face-to-face meetings and via online surveys. We published literature reviews regarding treatment for the key domains of PsA (arthritis, spondylitis, enthesitis, dactylitis, skin, and nail disease), and convened a new group to identify pertinent comorbidities and their effect on treatment. Finally, we drafted treatment recommendations for each of the clinical manifestations and assessed the level of agreement for the overarching principles and treatment recommendations among GRAPPA members, with an online questionnaire.RESULTS: Six overarching principles had at least 80% agreement among both health care professionals (HCPs; n=135) and patient research partners (PRPs; n=10). We developed treatment recommendations and a schema incorporating these principles for arthritis, spondylitis, enthesitis, dactylitis, skin, and nail disease, and comorbidities in the setting of PsA, using the GRADE process. Over 80% agreement was reached for approval of the individual recommendations and the overall schema.CONCLUSION: Herein, we present overarching principles and updated treatment recommendations for the key manifestations of PsA, including related comorbidities, based on a literature review and consensus of GRAPPA members (rheumatologists, dermatologists, other HCPs, and PRPs). Further updates are anticipated as the therapeutic landscape in PsA evolves.
UR - http://dx.doi.org/10.1002/art.39573
U2 - 10.1002/art.39573
DO - 10.1002/art.39573
M3 - Article
C2 - 26749174
SN - 2326-5191
VL - 68
SP - 1060
EP - 1071
JO - Arthritis & Rheumatology
JF - Arthritis & Rheumatology
IS - 5
ER -